ScripBristol Myers Squibb Company and Sanofi recently joined the ranks of companies cutting costs and jobs in 2024, although not necessarily for the same reasons, as first quarter earnings season got un
ScripThe state of the financial markets for biopharmaceutical companies in 2024 is about as unpredictable as the weather in San Francisco during the annual J.P. Morgan Healthcare Conference. The forecast f
ScripConditions look ripe for an uptick in M&A this year after a fairly quiet 2022, while other types of strategic deals are also expected to increase in the face of a challenging funding situation for bio
ScripThe first half of 2022 saw the NASDAQ Biotechnology Index lose a quarter of its value. Despite a tentative recovery since then, the IPO window is barely ajar and valuations remain well below the highs